Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

OUTLINE: This is a multi-center study. * Bevacizumab 15 mg/kg IV on day 1 * Erlotinib 150 mg po qd days 1-21 * Disease Assessment during even numbered cycles If no progressive disease observed, continue (combination or single agent- see below) until unacceptable toxicity or progressive disease. If progressive disease observed, treatment will be discontinued. * Cycles will be repeated every 21 days up to a total of 6 cycles. * Patients with non-progression after 6 cycles may stay on therapy (single agent erlotinib or the combination) until progressive disease or intolerable toxicity (at the physician discretion). * Patients who require discontinuation of bevacizumab may receive at investigator's discretion erlotinib alone on study until progression. * Patients who require discontinuation of erlotinib may receive at investigator's discretion bevacizumab alone until progression. ECOG Performance Status 2 Hematopoietic: * Absolute neutrophil count (ANC) \> 1,000 mm3 * Platelet count \> 100,000 mm3 * Hemoglobin \> 8 g/dl Hepatic: * Bilirubin \< 2 X upper limit of normal. * Aspartate aminotransferase (AST, SGOT) \< 2.5 X upper limit of normal or 5 X if liver involvement. Renal: * Urine protein:creatinine ratio 1.0 at screening Cardiovascular: * Blood pressure of \< 150/100 mmHg. * No history of unstable angina. * No history of New York Heart Association (NYHA) Grade II or greater congestive heart failure. * No history of myocardial infarction within 6 months prior to registration for protocol therapy. * No history of stroke within 6 months prior to registration for protocol therapy. * No clinically significant peripheral vascular disease.